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Study of factors which modify the development of norepineph-
rine-induced acute renal failure in the dog. Previous studies have
demonstrated that the fall in inulin clearance which occurs 3
hours after the intrarenal administration of norepinephrine can
be markedly attenuated by the prior administration of intrarenal
prostaglandin E2 (PGE). Since in the previous studies PGE led to
a marked increase in both renal blood flow and solute excretion,
we designed the present series of experiments to investigate
whether an increase in renal blood flow, solute excretion, or oth-
er factors were responsible for the protective effect in the norepi-
nephrine model. Two renal vasodilators, bradykinin and secre-
tin, were evaluated initially. Bradykinin administration prior to
norepinephrine administration had a protective effect similar to
that previously found with PGE, whereas secretin did not. Both
of these vasodilators increased renal blood flow to the same de-
gree, but only bradykiniri increased urine flow and solute excre-
tion. The fall in inulin clearance 3 hours after the administration
of norepinephrine was also attenuated by two diuretics (mannitol
and furosemide) which tended to increase renal blood flow. In
contrast, two natriuretic agents, which are also renal vasocon-
strictors (chlorothiazide and benzolamide), had no protective ef-
fect. Further, chlorothiazide and benzolamide obviated the pro-
tective effect of bradykinin. These studies demonstrate that there
are several types of pharmacologic agents which can modify the
magnitude of renal functional impairment resulting from extreme
renal ischemia. Although the mechanism of the protective effects
remain unclear, the findings are compatible with the view that
the protective effect noted with PGE, bradykinin, mannitol, and
furosemide may be related to an increase in osmolar excretion
which occurred with administration of each of these agents. This
potentially salutory effect (increased osmolar excretion), how-
ever, could be overcome by an agent (e.g., chlorothiazide or ben-
zolamide) which also increased renal resistance prior to the ad-
ministration of norepinephrine.
Etude des facteurs qui modiflent l'évolution de l'insuffisance ré-
nale aigue par Ia norépinéphrine chez le chien. Des travaux ante-
rieurs ont démontré que Ia chute de Ia clearance de l'inuline qui
survient 3 heures aprês l'administration intra-rénale de noré-
pinéphrine peut étre atténuée de facon importante par l'injection
intrarénale préalable de prostaglandine F2 (PGE). Puisque dans
les travaux antérieurs, Ia PGE a déterminé une augmentation
importante a Ia fois du debit sanguin renal et de l'excrétion de
substances dissoutes, cette série d'experiences a pour but de
savoir si une augmentation du debit sanguin renal ou de
l'excrétion de substances dissoutes ou bien d'autres facteurs
sont responsables de l'effet protecteur dans Ic modéle de Ia noré-
pindphrine. Deux vasodilatateurs rénaux, Ia bradykinine et Ia
secrétine ont été initialernent étudiés. L'administration de bra-
dykinine préalable a celle de norepinéphrine a un effet pro-
tecteur semblable a celui antérieurement observe avec Ia PGE
alors que Ia secrétine n'a pas cet effet. Ces deux vasodilatateurs
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augmentent Ic debit sanguin renal de Ia méme facon, mais seule
Ia bradykinine augmente le debit urinaire et l'excrétion de sub-
stances dissoutes. La chute de Ia clearance de l'inuline 3
heures après Ia norepinephrine est aussi atténuée par deux
diuretiques qui tendent a augmenter Ic debit sanguin renal (man-
nitol et furosémide). Au contraire, deux agents natriurétiques
qui sont aussi des vasoconstricteurs rénaux (chlorothiazide et
benzolamide) n'ont pas d'effet protecteur. De plus, ces deux
corps empéchent l'effet protecteur de Ia bradykinine. Ces etudes
démontrent qu'il y a plusieurs categories d'agents pharmacolo-
giques qui peuvent modifier l'importance de laltération fonc-
tionnelle qui résulte d'une ischémie rénale extreme. Quoique le
mécanisme de l'effet protecteur reste obscur, ces constatations
sont compatibles avec l'idée que l'effet observe avec Ia PUE, la
bradykinine, le mannitol et le furosémide puisse être lie a une
augmentation de l'excretion osmolaire qui est observée au cours
de l'administration de chacun de ces corps. Cet effet benéfique
potentiel (l'augmentation de l'excrétion osmolaire) peut, cepen-
dant, étre annulé par un agent (comme Ic chlorothiazide ou Ia
beuzolamide) qui augmente aussi Ia résistance rénale prealable-
ment a l'administration de norepinephrine.
In a recent study from this laboratory, we noted
that prostaglandin E2 (PGE), a potent renal vasodila-
tor, markedly attenuated the development of acute
renal failure induced by the prolonged intrarenal in-
fusion of norepinephrine [1]. The basis of this pro-
tective effect of PGE in the norepinephrine model,
however, was quite obscure. When norepinephrine
was infused in the renal artery at a dose of 1.0 jsg/
kg/mm for 40 mm, renal blood flow and urine flow
were reduced to essentially undetectable levels.
Three hours after discontinuing the norepinephrine,
inulin clearance was 3% of the value noted prior to
administration of the vasoconstrictor. When intra-
renal PGE was given prior to norepinephrine, the
fall in inulin clearance was markedly less than it was
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in the studies in which norepinephrine was given
alone. This finding was especially surprising since
the PGE infusion did not alter in any discernible
way the vasoconstrictor effect of norepinephrine.
During combined PGE and norepinephrine adminis-
tration, blood flow was still depressed (as measured
by either flow meter or microspheres) to the same
level found with norepinephrine alone. Thus, PGE
infusion did not alter the vasoconstrictor effect of
norepinephrine, but it did significantly modify the
magnitude of renal functional impairment. Whether
this protective effect of PGE was due to a subtle
hemodynamic action of the drug, to an effect of the
agent to increase urine volume and osmolar excre-
tion, or to a more direct action of this vasoactive
compound was not clear. The present studies were
designed to further investigate these possibilities.
Methods
Mongrel dogs, each weighing 14 to 26 kg, were
deprived of food 18 hours prior to study. The ani-
mals were anesthesized i.v. with 30 mg of sodium
pentobarbital per killogram of body weight, and ad-
ditional small doses were administered as needed
during the experiment to maintain light anesthesia.
After endotracheal intubation, the animals were
ventilated with a Harvard respirator (Harvard Ap-
paratus Co., Inc., Millis, Massachusetts). The fern-
oral vein and artery were cannulated. Following an
800-mg i.v. bolus of inulin, an infusion of Ringer so-
lution containing 2% inulin was given at 0.7 to 1.0
cc/mm through the femoral vein cannula. The femo-
ral artery was used for collecting blood samples. In
addition, the femoral arterial line was connected to
a pressure transducer and recorder (Hewlett-Pack-
ard Co., Waltham, Massachusetts) for continuous
monitoring of mean arterial blood pressure. A car-
diovascular catheter (Goodale Lubin 7F) was
threaded through the right carotid artery into the
left ventricle and was used for injecting radioactive
microspheres (3M Company, Nuclear Products, St.
Paul, Minnesota) to determine renal blood flow.
Test Norepinephrine &
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The bladder was exposed through a midabdominal
suprapubic incision, and the ureters were can-
nulated using polyethylene tubing (PE-160 to PE-
205). The left renal artery was exposed though a
small flank incision, and an electromagnetic flow-
probe (inside diameter, 2.5 to 3.5 mm; Zepeda In-
struments, Seattle, Washington) was fitted around
the vessel for continuous monitoring of renal blood
flow. Zero flow was determined with a tie placed
around the renal artery distal to the probe. The
probes were calibrated in vivo. A curved 21-gauge
scalp-vein needle was inserted into the renal artery
near its origin and was kept open with Ringer solu-
tion at 0.76 cc/mm. Experimental agents were in-
fused through this needle.
Total renal blood flow was also measured in most
studies with an indicator dilution modification of the
radioactive microsphere method as previously de-
scribed [2]. The nuclides used were 475c, '41Ce, and
85Sr. A different nuclide was used in each period
and the sequence of injection was altered from ex-
periment to experiment.
The following groups of studies were performed:
Group I: Norepinephrine alone (N = Ii). After
three 10-mm control clearance collections were ob-
tained, norepinephrine (1 g/kgImin) was infused in
the renal artery for 40 mm and then discontinued.
Three hours later, three additional clearance collec-
tions were made. Renal blood flow was measured
with radioactive microspheres in the control period
and 3 hours after norepinephrine. In addition, renal
blood flow of the experimental kidney was mon-
itored by electromagnetic flow probe throughout
the experiment in this and all subsequent groups of
studies. In four studies, renal blood flow was also
measured during norepinephrine administration.
Group II: Bradykinin (N = 5). The general pro-
tocol for the group-Il through VII studies is shown
in Fig. 1. In these remaining studies, a number of
test agents were used that had different effects on
renal blood flow and solute excretion. These agents
were specifically chosen to determine which of
ttt t
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collections collection
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collections
Fig. 1. Experimental protocol for the group II through VII studies.
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these alterations was responsible for attenuating the
fall in inulin clearance after norepinephrine. All
drugs were infused in the renal artery of the experi-
mental kidney to minimize possible systemic effects
of the test substance. In the group-LI studies, bra-
dykinin was used as an agent that, like PGE, would
increase both renal blood flow and solute excretion.
After three 10-mm control collections were ob-
tained, bradykinin (0.75 g!kg!min) was infused in-
trarenally at 0.76 mllmin. A timed urine collection
was obtained during this period. Fifteen minutes
later, norepinephrine (1 g/kg/min) was added to
the infusion, and both drugs were continued for 40
mm. Three hours later, an additional three clear-
ance collections were obtained. Renal blood flow
was measured with radioactive microspheres in the
control period, during bradykinin administration,
and 3 hours after discontinuing both drugs. In
this and all the following groups of studies, urinary
losses were carefully replaced with an equivalent
amount of Ringer solution.
Group III: Secretin (N = /1). To determine
whether the renal vasodilatation itself would be pro-
tective in the norepinephrine model, we infused se-
cretin (45 mU/kg/mm; Boots, Nottingham, Eng-
land) in place of bradykinin. This drug has been
shown to cause a marked increase in renal blood
flow with only trivial changes in sodium excretion
[3]. The protocol was otherwise similar to the
group-Il studies.
Group IV: Furoseinide (N = 7). To determine
whether an increase in solute excretion in associa-
tion with only a small change in renal blood flow
would be protective in the norepinephrine model,
we infused furosemide (4 mg/kg/hr) intrarenally.
The protocol was otherwise similar to the group-TI
studies.
Group V. Mannitol (N = II). To determine
whether protection would occur during a diuresis
induced with an osmotic agent, we infused 10%
mannitol intrarenally at 0.76 mllmin. Fifteen min-
utes later, norepinephrine was started and both
agents were continued simultaneously as in the oth-
er groups. The remainder of the protocol was simi-
lar to the group-IT studies.
Group VI: Chiorothiazide (N = 7). To determine
the effect of a diuretic agent which increased renal
resistance [4] and had its main site of action in the
distal nephron [5], we infused chlorothiazide (4 mg/
kg!hr). Otherwise, the protocol was similar to the
group-IT studies.
Group VII: Benzolarnide (N = 7). To determine
the effect of a diuretic which was a renal vasocon-
strictor and had its major site of action in the proxi-
mal tubule [6], we infused benzolamide (a carbonic
anhydrase inhibitor; 1 mg/kg/hr) intrarenally. In
these studies, the inulin infusion contained 300 mrvi
sodium bicarbonate to maintain arterial pH at ap-
proximately 7.4 during infusion of benzolamide.
Otherwise, the protocol was similar to the group-IT
studies.
Group VIII: Bradykinin and chiorothiazide (N =
6). To determine whether attenuating the vaso-
constrictor effect of chlorothiazide would have a
protective effect on inulin clearance in the norepi-
nephrine model, we performed this group of stud-
ies. The protocol was similar to the above groups,
except that 30 mm prior to the infusion of norepi-
nephrine, bradykinin (0.75 g/kg/min) was infused.
Fifteen minutes later, chlorothiazide (2 mglkglhr: in
preliminary experiments this lower dose of chloro-
thiazide was found to maintain the renal blood flow
above the control value) was added to the infusion
of bradykinin, and both agents were given for an
additional 15 mm. Norepinephrine infusion was
then started, and both bradykinin and chlorothia-
zide were continued for another 40 mm. Timed
clearance collections were obtained during the ad-
ministration of bradykinin, bradykinin and chloro-
thiazide, and 3 hours after the infusion of all three
drugs had been discontinued. Microsphere determi-
nations of renal blood flow were made during the
control period, bradykinin administration, and bra-
dykinin -1- chlorothiazide infusion.
Group IX: Bradvkinin and benzola,nide (N = 5).
To determine if another agent which increases both
sodium and osmolar excretion but tends to decrease
renal blood flow would attenuate the protective ac-
tion of bradykinin on inulin clearance in the norepi-
nephrine model, we performed this group of stud-
ies. The protocol was similar to the group-VITI
studies, but instead of chlorothiazide, benzolamide
(I mg/kg/hr) was added to the infusion of bradyki-
nm.
Inulin was measured using an autoanalyzer
(Technicon Corp., Ardsley, New York) and clear-
ances were calculated in the usual manner. Plasma
and urine osmolality were determined by freezing
point depression with an osmometer (Advanced In-
struments, Inc., Newton Highland, Massachu-
setts). Plasma and urine sodium concentrations
were determined by flame photometry (Instrumen-
tation Laboratory, Lexington, Massachusetts). Re-
sults are expressed as the mean I SEM and paired
and unpaired comparisons were made using Stu-
dent's t test.
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Results
Group I: Norepinephrine alone (N = 11). The re-
suits of these studies are summarized in Table 1.
During the control period, renal blood flow aver-
aged 195 16 mllmin, and inulin clearance averaged
41 3 mi/mm in the experimental kidney (EK).
Comparable values were obtained in the control
kidney (CK). During the 40-mm period of norepi-
nephrine infusion, renal blood flow in EK in this
and all subsequent groups was essentially zero as
determined by flow probe, and there was no mea-
surable urine output. In four studies, renal blood
flow in EK was also measured with radioactive mi-
crospheres during the norepinephrine infusion and
averaged 4 2 mL/min. Three hours after the nor-
epinephrine infusion was discontinued, renal blood
flow averaged 104 13 mllmin in EK, a value which
was significantly less than that found in the control
period (P < 0.01). Inulin clearance in the EK aver-
aged 2 1 mI/mm or 5% of the value obtained prior
to norepinephrine. Anuria was present in 5 of the 11
studies, whereas in the other six experiments urine
flow rate averaged 0.16 0.09 mllmin. In CK, renal
blood flow at 3 hours averaged 170 24 mI/mm, and
inulin clearance averaged 47 5 mllmin, values not
significantly different from those of control. Since
values from CK were also not markedly altered in
any of the other groups of studies, only the results
from EK will be presented in the remaining groups.
Group II: Bradykinin studies (N = 5). The results
of the group-IT studies are shown in Table 2. During
the administration of bradykinin alone, there was a
significant increase in renal blood flow from 227 to
290 mL'min, as well as increases in urine flow from
Table 1. Summary of norepinephrine studies (group l)a
Experimental kidney Control kidney
V
mi/mm
Ch,
mi/mm
RBF
mi/mm
UNaV
p.Eq/min
FENa
%
V
mi/mm
C1n
mi/mm
RBF
mi/mm
UaV
p.Eq/min
FENa
%
MAP
mm Hg
Control (N = ii) 0.34 41.6 195 75.3 1.7 0.27 47.0 189 70.3 1.3 142
7
3 hours after
norepinephrine
o 16 22h 104C 258b, c
12.0
102h, c 0.27
+0.05
47.2 170 70.4
10.5
1.4 135
4
a Abbreviations used: V, urine flow; Ca,, inulin clearance; RBF, renal blood flow; UNaV, urinary excretion of sodium; FENa, fractional
excretion of sodium: MAP, mean arterial pressure.
Represents the six studies in which there was return of urine flow in experimental kidney.
Cp <0.01.
dp <0.001.
Table 2. Summary of bradykinin and secretin studiesa
V
mi/mm
C1
mi/mm
RBF
mi/mm
UNaV
p.Eq/min
FENa
%
UosmV
p.Osm/min
MAP
mm Hg
Group II: Bradykinin + norepinephrine (N = 5)
Control 0.4 46.2 227 47.8 0.64 234 136
±0.17 ±4.0 ±38 ±6.5 ±0.17 ±50 ±18
P (control vs. bradykinin) < 0.01 NS <0.01 <0.01 < 0.05 <0.05 NS
Bradykinin 1.01 45.0 290 83.3 1.2 541 137
±0.3 ±5.1 ±34 +16 ±0.2 ±124 ±16
P (control vs. 3 hours) < 0.05 < 0.01 < 0.02 NS NS < 0.025 NS
3 hours after 0.25 25.3 104 29.4 1.30 125 141
bradykinin and ±0.05 ±6.0 ±36 ±7.0 ±0.7 ±29 ±18
norepinephrine
Group I!!: Secretin + norepinephrine (N = 1/)
Control 0.27 33.2 231 38.5 0.71 217 135
±0.04 ±2.5 ±25 ± 11.0 ±0.2 ±29 ±7
P (control vs. secretin) NS NS < 0.001 NS NS NS NS
Secretin 0.32 35.4 282 45.8 0.81 227 137
±0.05 ±4.2 ±24 ±15 ±0.3 ±42 ±6
P (control vs. 3 hours) <0.05 < 0.0001 <0.001 NS < 0.05 NS NS
3 hours after 0.62 3.9 144 50.4 14.7 352 137
secretin and ±0.1 ±1.4 ±15 ±11.0 ±5.3 ±120 ±6
norepinephrine
a Abbreviations are defined in Table 1. UosmV is osmolar excretion.
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Secretin Benzolamide Bradykinin &
Chiorothiazide Bradykinin & benzoamide
chiorothiazide
Fig. 2. Percentage reco%'erv of inn/in clearance at 3 hours after infusion of norepinephrine (group I) and test agents + norepinephrine
(groups II to IX).
0.4 to 1.0 mllmin, sodium excretion from 47 to 83
sEq/min, and osmolar excretion from 234 to 541
pOsm/min. Bradykinin, however, failed to obviate
the vasoconstrictor effect of norepinephrine since
renal blood flow and urine flow were essentially ze-
ro when both bradykinin and norepinephrine were
infused simultaneously. Three hours following the
discontinuation of both drugs, renal blood flow av-
eraged 104 mllmin, and inulin clearance was 54% of
the control value (Fig. 2), This later value, how-
ever, was significantly greater than the results
found with norepinephrine alone (group I, P <
0.005). Thus, significant preservation of inulin
clearance occurred in these studies when bradyki-
nm was administered prior to and during the in-
fusion of norepinephrine. In addition, fractional so-
dium excretion was 1.3%, a value significantly less
than that in the group-I studies (P < 0.05). This de-
gree of protection of inulin clearance is quite similar
to the previous studies in which prostaglandin E2
had been administered prior to and during the in-
fusion of norepinephrine [I].
Group Ill: Secretin studies (N = 11). The results
of this group of studies are shown in Table 2 and
Fig. 2. Secretin was chosen as an agent which
would give similar changes in renal blood flow as
occurred with bradykinin but without a significant
change in urine flow or sodium excretion [3]. Dur-
ing the administration of secretin alone, renal blood
flow increased from 231 to 282 mllmin. This change
in blood flow was quite comparable to that found
above in the group-IT studies, but in contrast to the
previous group, secretin did not significantly
change urine flow, sodium excretion, or osmolar ex-
cretion during this 15-mm period. With the initiation
of the norepinephrine infusion, renal blood flow and
urine flow fell to essentially zero and persisted at
this level for the 40 mm of norepinephrine infusion.
Three hours after the discontinuation of both drugs,
renal blood flow had partially returned to 144 15
mllmin, but inulin clearance averaged only 3.9 1.4
mllmin compared with the initial inulin clearance of
33.2 2.5 ml!min or 11% of the control value (Fig.
2). This latter value was not significantly different
from the 5% value found in the group-I studies
(Table 1). Yet, urine flow more than doubled, and
fractional sodium excretion averaged 14.7% 3 hours
after norepinephrine infusion (Table 2). Thus, there
was no protection of inulin clearance in this group
in spite of the fact that renal blood flow had been
increased prior to norepinephrine administration
and that this increase in blood flow was similar to
that achieved in the group-Il studies.
Group IV: Furosemide studies (N = 7). The re-
suits of these studies are shown in Table 3. Furose-
mide was chosen as a potent diuretic agent which
also had a tendency to increase renal blood flow 1171.
During furosemide administration alone, there was
an increase in renal blood flow in five of the seven
studies and essentially no change in the other two
experiments with a mean increase from 241 to 286
mllmin. Because of this variable effect, this change
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Table 3. Summary of furosemide and mannitol studies
was just below the 0.05 level of statistical signifi-
cance. Urine flow increased from 0.3 to 5.7 mI/mm,
sodium excretion rose from 49 to 737 Eq/min, and
osmolar excretion rose from 220 to 1818 Osm/min.
Norepinephrine infused simultaneously with fu-
rosemide led to a fall in renal blood flow and urine
flow to essentially zero. Three hours after both
drugs were discontinued, renal blood flow had re-
turned to 52% of the control value, and inulin clear-
ance was 30% of the control measurement (Fig. 2).
This latter value was significantly greater than the
finding in the group-I studies (P < 0.005). In addi-
tion, both urine flow and fractional sodium excre-
tion were increased at 3 hours (Table 3). Thus, sig-
nificant protection of inulin clearance occurred
when furosemide was infused prior to norepineph-
rine.
Group V. Mannitol studies (N = 11). The results
of this group of studies are also shown in Table 3.
Mannitol was chosen as a diuretic with a mecha-
nism of action quite different from that of furose-
mide, but yet as a diuretic with a tendency to in-
crease renal blood flow. Mannitol alone caused an
increase in renal blood flow in five of the eight stud-
ies in which it was measured, with a mean increase
from 211 to 219 mllmin. Renal blood flow measure-
ments were not obtained in three studies. There was
a significant increase in urine flow from 0.3 to 0.7
mllmin, sodium excretion from 60 to 88 Eq/min,
and osmolar excretion from 269 to 532 Osm/min.
During the subsequent 40 mm when norepinephrine
and mannitol were given together, renal blood flow
and urine flow were essentially zero. Three hours
after the discontinuation of both drugs, renal blood
flow had returned to 59% of the control value, and
inulin clearance had returned to 43% of the control
value (Fig. 2). This value was also significantly
greater than the results of the group-I studies (P <
0.005) were. Thus, mannitol, a diuretic with a mech-
anism of action quite different from that of furos-
emide, also offered significant protection of inulin
clearance when given prior to norepinephrine. Three
hours after norepinephrine infusion, urine flow was
increased in some but not all studies, and fractional
sodium excretion rose from 1 . I in the control period
to 6.2%.
Group VI: Chiorothiazide studies (N = 7).
Chlorothiazide was chosen as a diuretic which, in
contrast to furosemide and mannitol, would consis-
tently decrease renal blood flow [41. The results of
these studies are summarized in Table 4. Chloro-
thiazide alone caused a significant decrease in renal
blood flow (239 to 203 mI/mm) and inulin clearance
(30 to 21 mI/mm). In contrast, urine flow increased
from 0.3 to 1.4 mI/mm, sodium excretion rose from
32 to 198 Eq/min, and osmolar excretion increased
from 229 to 646 .rOsm/min. During the administra-
tion of chiorothiazide and norepinephrine, renal
blood flow and urine flow were essentially zero.
Three hours after the discontinuation of both drugs,
renal blood flow averaged 55% of the control value,
but inulin clearance averaged only 10% of the con-
V Ca, RBF Uç,V FE5 UmV MAP
in//ui/n in//mm in//in in pEq/inin c4 pOs,n/inin mm Hg
Group IV I umomemn/e 4 norepinephrine (N — 7)
Control 0.37 30.1 241 48.9 0.99 220 1452.7 +24
P (control vs. furosemide) < 0.0001 NS NS 0.001 < 0.001 < 0.00 I NS
Furosemide 5.7 32.6 286 737.1 16.8 1818 14346 36 -'-3.0 298 -'-6
P (control vs. 3 hou;s) < 0.02 < 0.001 < 0.01 < 0.05 0.001 <0.001 NS
3 hours after 0.98 11.7 125.0 115.5 11.3 238 132
furosemide and 0.2 -'-2.7 ÷68
norepinephrine
Group I i4(liIflhI(i/ 0(1l'p10 ephiin C (N Ii)
Control 0.28 36.0 211 60.8 1.1 269 136
-'-0.05
I' (control vs. mannitol) 0.001 NS NS < 0.05 <0.05 <0.05 < 0.05
Mannitol 0.74 32.0 219 88.0 1.6 532 135
÷0.08 -'-3.6 13 -'-0.4
P (control vs. 3 hours) NS < 0.001 0.001 NS e- Q5 NS NS
3 hours after 0.58 15.7 124 82.4 6.5 267 122
mannitol and
-'-2.1 25.0 ÷2.8 110
norepinephrine
Abbreviations are defined in Table 1.
N = 5 studies.
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Table 4. Summary of chlorothiazide and benzolamide studies
V C1 RBF UV
tn//rn in tn//ruin rn//ruin .rEq ruin
FE Ui,smV MAP
Ostnirnin run, Hg
trol value, similar to that in group-I (norepinephrine
alone) and group-Ill (secretin) studies (Fig. 2). Yet,
as was also the case in the secretin studies, urine
flow and fractional sodium excretion were both
markedly increased 3 hours after norepinephrine.
Thus, chiorothiazide, a diuretic which decreased
renal blood flow, did not attenuate the fall in inulin
clearance, but it did prevent the development of
anuria as was seen in many of the group-I studies.
Group VII: Benolaniide studies (N = 7). The re-
sults of this group of studies are shown in Table 4.
Benzolamide was chosen as a diuretic which like
chlorothiazide would decrease renal blood flow but
whose major site of action was in the proximal tu-
bule [61. Benzolamide caused a significant decrease
in renal blood flow from 207 to 184 mllmin, whereas
urine flow increased from 0.3 to 1.4 mllmin, sodium
excretion rose from 41 to 200 zEqImin, and osmolar
excretion from 210 to 633 rOsm/min. The addition
of norepinephrine reduced renal blood flow to es-
sentially zero. Three hours after both drugs were
discontinued, renal blood flow averaged 66% of the
control values, and inulin clearance averaged 7% of
the control measurement (Fig. 2). In this group of
studies, urine flow was not increased, and fractional
sodium excretion was 3.9% 3 hours after norepi-
nephrine. Thus, benLolamide, another diuretic
which decreases renal blood flow, did not offer sig-
nificant protection in this model of acute renal fail-
ure.
Group VIII: Bra dvk in in and chiorothiazide stud-
ies (N = 6). The results of this group of studies are
shown in Table 5. This combination of drugs was
used to see if the maintenance of renal blood flow
and solute excretion above control levels in the
presence of chlorothiazide would offer significant
protection. Bradykinin was started first and caused
a significant increase in renal blood flow (249 to 395
mlimin), urine flow rate (0.6 to 1.7 mllmin), sodium
excretion (71 to 177 pFqlmin), and osmolar excre-
tion (292 to 503 iOsm/min). The addition of chioro-
thiazide led to further increases in urine flow to 2.6
mllmin, sodium excretion to 271 Eq/min, osmolar
excretion to 917 Osm/min, and a modest fall in
renal blood flow to 310 mI/mm, a value which was
still significantly higher (P < 0.05) than the value
obtained during the control period. In addition, in-
ulin clearance fell from 40 to 35 mL/min (P <0.001).
The addition of norepinephrine to these other two
agents decreased renal blood flow and urine flow to
essentially zero. Three hours after the discontin-
uation of all three agents, inulin clearance averaged
6% of the control values, a value not different than
that found with the group-I or group-Ill studies (Fig.
2). Thus, even though renal blood flow, urine flow,
and solute excretion were maintained above control
levels prior to the administration of norepinephrine,
there was no significant protection at 3 hours in this
group of studies.
Group IX: Brudykinin and henzola,nide studies
Group VI. Ch/orothiu.ide + norepinephrine (N — 7)
Control 0.34 30.1 239 31.8 0.84 229 137
2.2 --9.0 *7
P (control vs. chlorothiazide) . 0.001 < 0.01 0.01 <. 0.001 <. 0.005 < 0.005 NS
Chlorothiazide 1.4 21.4 203 198.0 7.1 646 128
1.2 27.0 6
P (control vs. 3 hours) < 0.001 < 0.0001 < 0.001 <0.0! < 0.001 < 0.001 NS
3 hours after 1.03 3.0 128 87.0 16.0 199 134
chiorothiazide and *26 *3.1 *56
norepinephrine
Group VII: Benzo/o,nide m norepinephrine (N 7)
Control 0.25 32.9 207 40.6 0.94 210 1530.06 *81 *22
P (control vs. benzolamide) ... 0.005 NS < 0.001 0.001 0.02 0.02 NS
Benzolamide 1.4 32.0 184 199.6 4.6 633 148
6.0 42.0 1.0 121 *5
P (control vs. 3 hoursj NS <. 0.001 < 0.001 0.01 < 0.005 — NS
3 hours after 0.2 2.6 136 11.0 3.9 — 141
benzolamide and 3.0 *1.1 —
norepinephrine
a Abbreviations are defined in Table 1.
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Table 5. Summary of bradykinin + chiorothiazide + norepinephrine studies (group VIII: N
V Cm
mi/mimi mi/mm
RBF
mi/mm
UNaV FENa
pJJq/min %
UosmV
.tOsm/min
MAP
mm Hg
Control 0.59 45.4 249 71.2 0.9 292 133
P (control vs. bradykinin) < 0.01 NS <0.01 < 0.05 <0.05 < 0.02 NS
Bradykinin 1.7 40.3 395 177.0 3.0 503 131
0.14
P (bradykinin vs.
chlorothiazide) < 0.02 < 0.001 < 0.02 < 0.01 <0.01 <0.02 NS
Bradykinin + 2.6 35.2 310 271.0 4.5 917 129
chlorothiazide 1.8
P (control vs. 3 hours) NS < 0.001 — NS NS < 0.05 NS
3 hours after 0.16 2.5 — 21.3 3.1 133 116
bradykinin. —
chiorothiazide +
norepinephrine
Abbreviations are defined in Table 1.
Table 6. Summary of bradykinin + benzolamide + norepinephrine (group IX; N =
V Ca RBF UNaV FEN. UosmV MAP
mi/mm mi/aim mi/mm p.Eq/min pOsm/min ,flm Hg
Control 0.25 28.0 170 26.0 0.7 163 147.0
0.08 3.3 24 8.0 0.3 27 5.8
P (control vs. bradykinin) <0.01 NS < 0.05 < 0.01 < 0.02 <0.05 NS
Bradykinin 2.3 26.4 321 246 6.8 694 145
0.4 3.4 36 46 0.2 99 5
P (bradykinin vs. NS NS < 0.025 NS NS NS NS
benzolamide)
Bradykinin + 2.5 25.0 243 227 6.9 687 138
benzolamide 0.4 + 3.3 25 41 0.2 68 5
P (control vs. 3 hours) < 0.05 < 0.001 < 0.05 NS < 0.01 < 0.05 < 0.01
3 hours after 0.11 2.5 147.0 13.0 3.9 51 124
bradykinin, 0.03 1.0 5.8 4.6 2.3 13
benzolamide +
norepinephrine
Abbreviations are defined in Table I.
(N = 5). The results of this group of studies are
shown in Table 6. This combination of agents was
chosen to determine if another agent which increas-
es both sodium and osmolar excretion but tends to
decrease renal blood flow would obviate the pro-
tective effect of bradykinin on inulin clearance. Bra-
dykinin increased renal blood flow (170 to 321 mu
mm), urine flow (0.25 to 2.3 mllmin), sodium excre-
tion (26 to 246 .tEq/min), and osmolar excretion
(163 to 694 pQsm!min). The addition of ben-
zolamide led to a small further increase in urine
flow to 2,5 mllmin. Renal blood flow decreased to
243 mllmin, a value which was still significantly
higher (P <0.05) than the value obtained during the
control period. Inulin clearance, urinary sodium,
and osmolar excretion did not change significantly.
The addition of norepinephrine to these other two
agents decreased renal blood flow and urine flow to
essentially zero. Three hours after discontinuation
of all three agents, inulin clearance averaged 9% of
the control, a value not different than that found
with the groups-I and -III studies (Fig. 2). Thus,
even though renal blood flow, urine flow, and solute
excretion were maintained above control levels pri-
or to the administration of norepinephrine, there
was no significant protection of inulin clearance at 3
hours in this group of studies.
Discussion
In a recent study evaluating the norepinephrine
model of acute renal failure, we demonstrated that
the intrarenal infusion of PGE significantly attenu-
ated the acute fall in inulin clearance in this model
[11. Inulin clearance 3 hours after discontinuing nor-
epinephrine averaged 52% of the control value in
dogs pretreated with PGE, but in the animals given
only norepinephrine alone, the inulin clearance av-
eraged only 7% of the control value. Since PGE is
both a potent renal vasodilator and an agent which
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increases urine flow and solute excretion [8—101, it
seemed reasonable to consider the possibility that
the protection of renal function offered by PGE in
this model might be related to one or a combination
of these factors. It seemed difficult to attribute this
phenomenon to an effect of PGE on renal resistance
itself, since the drug did not attenuate in any dis-
cernible manner the marked vasoconstriction seen
with norepinephrine. Yet, it seemed possible that
the PGE-related increase in renal blood flow initi-
ated some secondary event which was ultimately
important in offering protection in this model. In
any case, the present series of studies were de-
signed to evaluate several of the potential mecha-
nisms for the protective effect of PGE in the norepi-
nephrine model.
The first two agents used were potent vasodila-
tors which had quite different effects on urine flow
and solute excretion. Bradykinin was used because,
like PGE, it causes an increase in renal blood flow
as well as urine flow and solute excretion [111. Se-
cretin was chosen as the other renal vasodilator be-
cause a recent study demonstrated that this agent
could cause a marked increase in renal blood flow
with only small changes in urine flow and solute ex-
cretion [31. The results of these studies are shown in
Table 2 and Fig. 2. Although renal blood flow was
increased to a similar degree in the two groups, only
bradykinin demonstrated significant protection of
inulin clearance at 3 hours. In contrast, the inulin
clearance in the secretin studies was not significant-
ly different from that found in the group-I studies in
which norepinephrine was given alone. Since secre-
tin afforded no protection and did not increase urine
flow or solute excretion, it seemed reasonable to
suggest from these studies that an increase in urine
flow and/or solute excretion might be critical to the
protective effect.
To further investigate this possibility, we studied
two diuretic agents, furosemide and mannitol,
which have different mechanisms of action and
have only a modest effect on renal hemodynamics
(Table 3 and Fig. 2). Both diuretics increased urine
flow, sodium, and osmolar excretion and caused a
significant degree of protection when compared to
the group-I studies (norepinephrine alone) or the
group-Ill studies (secretin). Although both agents
tended to increase renal blood flow, the changes did
not achieve statistical significance. Thus, these
studies were also compatible with the view that
changes in urine flow and solute excretion were im-
portant in the protective action of these various
agents. To test this possibility further, we studied
two diuretics which are known to decrease renal
blood flow as well as increase urine flow and solute
excretion.
Chlorothiazide was chosen as one of the agents
since its major site of action is felt to be in the more
distal portion of the nephron [51. Benzolamide was
used since its major site of action is in the proximal
tubule [61. Both agents led to the expected decrease
in renal blood flow and increase in urine flow and
solute excretion, but neither agent offered any pro-
tection when compared to the results of the group-l
studies (Table 4 and Fig. 2).
The results of all of these studies plus the pre-
vious PGE experiments are summarized in Table 7.
Several points are worthy of note. All of the agents
which are protective increase urine flow and solute
excretion. In addition, none of these drugs increase
renal resistance. An agent which increases renal
blood flow without altering solute excretion (secre-
tin) has no protective effect in the norepinephrine
model. Those agents which increase both solute ex-
cretion and renal resistance (chlorothiazide and
benzolamide) do not alter the fall in inulin clearance
seen with norepinephrine. One possible inter-
pretation of these complex findings is that enhanced
Table 7. Summary of changes in renal blood flow, urinary sodium and osmolar excretion, and protection of inulin clearance with various
test agents
Test agents Protection
Urinary sodium
excretion
Urinary osmolar
excretion
Renal blood
flow
Prostaglandin E + I I I I
Bradykinin + I I I I
Furosemide + I I I I I I I
Mannitol + I I I
Chlorothiazide — I I I
Benzolamide — I I I
Secretin — —* — I I
Bradykinin + — I I I —*
chlorothiazide
Bradykinin + I I I I
benzolamide
236 Patak et at
solute excretion is indeed the primary protective
factor but that this effect could be counterbalanced
in the chlorothiazide and benzolamide studies by a
hemodynamic action of the diuretic drugs. An alter-
native possibility is that some other effect other
than an increase in solute excretion was critical to
offering protection. To test this former possibility,
we performed the group-Vu! and -IX studies. Bra-
dykinin was initially given in both of these studies
and markedly increased both blood flow and solute
excretion. The addition of either chiorothiazide or
benzolamide to the infusate decreased renal blood
flow from 395 to 310 mllmin (chlorothiazide) and
321 to 243 mI/mm (benzolamide), These later values
were lower than those with bradykinin alone, but
still higher than the control values prior to bradyki-
nm. In contrast to the results with bradykinin alone,
there was no protective effect with either combina-
tion of agents (Tables 5 and 6, Fig. 2) even though
urine flow and solute excretion were as high or high-
er as with bradykinin alone. These findings are com-
patible with the previously noted suggestion that
protection in the norepinephrine model may be pri-
marily related to enhanced urine flow and solute ex-
cretion, but that this effect may be overcome by
some other action of chiorothiazide, benzolamide,
and perhaps other compounds which also increase
renal resistance. Alternatively, an increase in solute
excretion may not be as important in providing pro-
tection in this model as previously inferred [16, 17].
Other possible interpretations of these findings
should be considered. For example, Torres et a!
have found that the administration of indomethacin,
an inhibitor of prostaglandin synthesis, accentuates
the magnitude of renal functional impairment in
glycerol-induced acute renal failure 1121. Thus, it is
possible that alterations in prostaglandin synthesis
may be of pathogenic significance in the initiation
and/or maintenance of various models of acute re-
nal failure. In this regard, protective agents such as
furosemide 113, 14] and bradykinin [10, 15] do in-
deed increase renal PGE synthesis, whereas secretin
[15] and chlorothiazide [13] do not. Since there is
not adequate information on the PGE synthesis rate
for all of these agents, the relationship of the prosta-
glandin system to these results will have to remain
speculative.
The mechanism responsible for the deleterious
effect of chlorothiazide and benzolamide demon-
strated in the group-VIII and -IX studies (Tables 5
and 6) remains unclear. Even though renal blood
flow was elevated above the control level and solute
and osmolar excretion was as high or higher than
with bradykinin, chlorothiazide and benzolamide
still prevented the protective effect seen with brady-
kinin alone (Table 2). It is worthy of note, however,
that both renal blood flow and GFR fell when
chlorothiazide was given (and renal blood flow fell
when benzolamide was administered) either alone
or in combination with bradykinin, prior to norepi-
nephrine administration. Since there are no direct
measurements of glomerular dynamics with chloro-
thiazide and benzolamide, it would be speculative
to attempt to discuss whether these changes were
due to a change in renal blood flow itself, an effect
on segmental renal resistance, an alteration in the
ultrafiltration coefficient, or possibly a combination
of these factors. In any case, it seems possible that
the hemodynamic effect of chiorothiazide and ben-
zolamide may in some manner potentiate the action
of norepinephrine, enhance the degree of cellular
destruction, and thus obviate the protective effect
of bradykinin demonstrated in the group-Il studies.
In addition to the effect on inulin clearance, nu-
merous of the test agents also modified urinary flow
and sodium and osmolar excretion, or both. As is
shown in Table 1, the urinary composition in the
nonanuric norepinephrine studies was quite similar
to that found in patients with various clinical forms
of acute renal failure [18]. Urinary flow was re-
duced, but fractional sodium excretion was marked-
ly increased 3 hours after norepinephrine. Of the
protective agents, bradykinin administration re-
duced fractional sodium excretion when compared
to the results in the group-I studies (1.3 vs. 10.2%
with norepinephrine alone, P < 0.05). Furosemide
and mannitol both increased urine flow 3 hours after
norepinephrine whereas bradykinin did not. Of
these agents which had no protective effect on in-
ulin clearance, both secretin and chlorothiazide
converted the norepinephrine model from a severe
oliguric to a polyuric form of acute renal failure (Ta-
bles 2 and 4). All of these findings warrant further
consideration since Anderson et al recently found a
significantly improved prognosis in patients with
nonoliguric renal failure when compared to those
with oliguric forms of the syndrome [19].
In summary, these studies demonstrate the abili-
ty of several agents to significantly modify the mag-
nitude of renal functional impairment in a vaso-
constrictor model of acute renal failure. Both the
reduction in inulin clearance and the development
of oliguria, or both, were altered by only a brief phar-
macologic intervention prior to the ischemic insult.
These studies suggest that the magnitude of func-
tional change caused by a given ischemic insult may
indeed be modified by an appropriate and prompt
therapeutic maneuver.
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